Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAC: Ebola Vaccines in Children and Adults
NCT02876328Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2017
- Primary completion
- Dec 2019
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of zabdeno, Ebola Zaire vaccine (live, attenuated), Mvabea in Ebola virus disease (EVD), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2017; status: completed.
02
Drugs
zabdenoEbola Zaire vaccine (live, attenuated)Mvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02876328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876328.